Azure Biotech

Azure Biotech, a private biotechnology company, was founded to address critical gaps in women's health. The company's core mission is to develop novel formulations of lasofoxifene, specifically targeting vulvovaginal atrophy (VVA), a condition affecting over 32 million postmenopausal women in the U.S. Azure Biotech aims to empower women to navigate life's natural cycles with confidence and joy through innovative, localized treatments.

Notable figures affiliated with Azure Biotech include experts with extensive experience in pharmaceuticals and women's health. The company has secured rights from Ligand Pharmaceuticals to develop lasofoxifene, showcasing its strong strategic partnerships. Azure Biotech's key achievements include advancing the formulation of lasofoxifene for VVA, positioning itself as a leader in addressing this underserved market. The overall impact of Azure Biotech lies in its potential to significantly improve the quality of life for millions of women experiencing postmenopausal conditions.